During the second day of the 36th Annual J.P. Morgan Healthcare Conference, Amgen and Mylan highlighted their progress with biosimilar therapies, while Roche and Sanofi focused on progress with innovator products and combinations that may help insulate them from biosimilar and follow-on competition.
During the second day of the 36th Annual J.P. Morgan Healthcare Conference, Amgen and Mylan highlighted their progress with biosimilar therapies, while Roche and Sanofi focused on progress with innovator products and combinations that may help insulate them from biosimilar competition.
Amgen’s Biosimilars Portfolio Eyes a Share of $65 Billion in Global Sales
Amgen’s chairman and CEO, Bob Bradway, reported that biosimilars will provide an important driver of Amgen’s long-term growth; in addition to launching its adalimumab biosimilar (Amjevita) in the European Union during 2018, and receiving an approval for its bevacizumab biosimilar (Mvasi) last year, Amgen has filed its ABP 980 (trastuzumab) biosimilar for regulatory approval, and is in phase 3 development of ABP 710 (infliximab) and ABP 798 (rituximab) biosimilars.
Amgen is in phase 1 development of an eculizumab biosimilar, and process development of a cetuximab biosimilar, as well as 3 additional molecules. In total, the originator drugs that Amgen’s biosimilars are targeting totaled approximately $65 billion in worldwide sales in 2017, said Bradway.
At the same time, Amgen expects that it will be able to retain a substantial hold on market share for 2 of its originator biologics that face upcoming biosimilar competition. Bradway reported that Amgen’s reference pegfilgrastim (Neulasta) has seen strong success with its Onpro kit, sales of which accounted for 60% of Neulasta sales in the fourth quarter of 2017.
Bradway also noted that Amgen continues to “make strategic investments” in its originator etanercept (Enbrel), which will retain its US patent exclusivity through 2029, despite the approval of a biosimilar, Erelzi.
Mylan: Pegfilgrastim Biosimilar a Potential “Mid-Year 2018 Opportunity”
In a “fireside chat” presentation, Heather Bresch, Mylan’s CEO, and Rajiv Malik, company president, also highlighted progress with biosimilars. Bresch noted Mylan’s 2017 win with the approval of “our Herceptin,” Mylan’s Ogivri.
Bresch, saying that her company has one of the most robust biosimilar pipelines in the industry, did note that the market for biosimilars—as well as for generics like the multiple sclerosis drug glatiramer acetate (Copaxone), which she said was in a similar “bucket” with respect to marketplace challenges—will present a steep industry learning curve as US states address issues of substitution of drugs. Ultimately, she said, “affordability and access is going to drive necessity” for these products.
Malik added that Mylan’s pegfilgrastim biosimilar, which received a complete response letter from the FDA in October 2017, may be a “mid-year 2018 opportunity” for FDA approval. Malik said that “we believe that our mostly scientific issues have bene addressed,” and that the quality issues related to its manufacturing facility have been resolved.
Roche Looks to Combinations for Herceptin, Rituxan
Roche, maker of numerous biologics targeted by biosimilar developers, noted its December 2017 approval of pertuzumab (Perjeta) plus trastuzumab (Herceptin) in HER2-positive early breast cancer, a combination that could help the company to forestall competition from Mylan’s biosimilar trastuzumab when launched.
Additionally, with oncoming biosimilar competition for its reference rituximab, Rituxan, Roche highlighted positive results of studies of its polatuzumab vedotin plus bendamustine versus rituximab plus bendamustine in phase 2 study in treating B-cell malignancies. It also reports that its development program of venetoclax includes venetoclax plus rituximab versus bendamustine plus rituximab in patients with chronic lymphoid leukemia, acute myeloid leukemia, non-Hodgkin lymphoma, and multiple myeloma.
Roche also noted the successful recent launch of its multiple sclerosis drug ocrelizumab (Ocrevus), saying that the therapy has achieved a “broad base of prescribers and a high level of US insurance coverage,” as well as the potential of its atezolizumab (Tecentriq) to achieve new therapeutic combinations by 2020. Tecentriq is currently under investigation for combination with such drugs as bevacizumab (Avastin) for the treatment of non-small cell lung cancer.
Sanofi Eyes Sotagliflozin in the Face of Follow-on Insulin Competition in the Diabetes Market
Olivier Brandicourt, CEO of Sanofi, highlighted the company’s work on sotagliflozin for the treatment of type 1 and type 2 diabetes. Sanofi has faced substantial competition for its insulin products in the United States since Boehringer Ingelheim launched its follow-on insulin glargine (Basaglar), and now finds 2 of its patents for its reference product under review by the US Patent Trial and Appeal Board after a challenge by Mylan.
According to Brandicourt, Sanofi showed steady financial performance despite its decline in diabetes sales (expected to total 6% to 8% for the 2015 to 2018 period), but nevertheless, the company sees sotagliflozin as promising on its positive data showing weight reduction, improved time in range in type 1 diabetes, strong glycated hemoglobin reduction, and reduction in the number postprandial glucose excursions, with no increase in hypoglycemia.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.